Skip to Content

Fertinex (urofollitropin) Disease Interactions

There are 6 disease interactions with Fertinex (urofollitropin):

Major

Follicle Stimulating Hormone (Includes Fertinex) ↔ Adrenal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Adrenal Insufficiency, Hyperadrenocorticism

The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled adrenal dysfunction. Uncontrolled adrenal dysfunction may involve the pituitary gland and be associated with a tumor or other dysfunction. Administration of FSH may exacerbate the condition.

References

  1. "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc, Norwell, MA.
  2. "Product Information. Follistim (follicle stimulating hormone)." Organon, West Orange, NJ.
Major

Follicle Stimulating Hormone (Includes Fertinex) ↔ Thyroid Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Hyperthyroidism, Hypothyroidism

The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled thyroid dysfunction. FSH is composed of both an alpha and beta subunit. The amino acid sequence of the alpha subunit of FSH is identical to that of TSH. Therefore, FSH may have weak TSH receptor- binding and activation.

References

  1. "Product Information. Follistim (follicle stimulating hormone)." Organon, West Orange, NJ.
  2. "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc, Norwell, MA.
Major

Follicle Stimulating Hormone (Includes Fertinex) ↔ Tumors

Severe Potential Hazard, High plausibility

Applies to: Neoplasia -- Estrogen Dependent

The use of follicle stimulating hormone is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (ovary, breast, uterus) and in patients with pituitary tumors. FSH is required for normal sex hormone production, which may be detrimental in these patients. Patients in later reproductive life have a greater predisposition to endometrial carcinoma.

References

  1. "Product Information. Follistim (follicle stimulating hormone)." Organon, West Orange, NJ.
  2. "Product Information. Gonal-F (follicle stimulating hormone)." Serono Laboratories Inc, Norwell, MA.
Major

Gonadotropins (Includes Fertinex) ↔ Thromboembolism

Severe Potential Hazard, Moderate plausibility

Applies to: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder, Obesity

Thromboembolic events, including venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebrovascular occlusion (stroke), and arterial occlusion resulting in loss of limb, have been reported during administration of gonadotropin therapy, both in association with and independent of the Ovarian Hyperstimulation Syndrome. Therapy with gonadotropins should be administered cautiously to patients with or predisposed to thromboembolism.

References

  1. "Product Information. Humegon (menotropins)." Organon, West Orange, NJ.
Major

Urofollitropin (Includes Fertinex) ↔ Intracranial Tumors

Severe Potential Hazard, Moderate plausibility

Applies to: Brain/Intracranial Tumor, Pituitary Tumor

The use of urofollitropin is contraindicated in the presence of any intracranial lesion or tumor.

Moderate

Gonadotropins (Includes Fertinex) ↔ Pulmonary Conditions

Moderate Potential Hazard, Moderate plausibility

Applies to: Pulmonary Impairment

Serious pulmonary conditions such as atelectasis, acute respiratory syndrome, and exacerbation of asthma have been reported in women treated with gonadotropins. Caution and monitoring is advised if used in women with pulmonary conditions.

Fertinex (urofollitropin) drug Interactions

There are 2 drug interactions with Fertinex (urofollitropin)

Fertinex (urofollitropin) alcohol/food Interactions

There is 1 alcohol/food interaction with Fertinex (urofollitropin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide